科源制药 reported revenue of ¥0.33B for the period ended 2026-06-30, +45.5% year on year. Net income was ¥0.06B, a 19.5% net margin on a 55.7% gross margin. The largest revenue line is 化学药品制剂 at 50% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.33B | +45.5% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.06B | +51.2% |
| Gross margin | 55.7% | Net margin 19.5% |
| Revenue Q/Q | +5.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 化学药品制剂 | ¥0.17B | 50.1% |
| 化学原料药 | ¥0.10B | 30.7% |
| 中间体 | ¥0.05B | 15.8% |
| 其他(补充) | ¥0.01B | 3.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.15B | 44.3% |
| R&D | ¥0.01B | 3.4% |
| SG&A | ¥0.10B | 30.0% |
| Tax & other | ¥0.00B | 0.3% |
| Item | Amount |
|---|---|
| Total assets | ¥1.91B |
| Total liabilities | ¥0.48B |
| Shareholders' equity | ¥1.43B |
| Equity / assets | 74.8% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 66% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
金禄电子 ・ 聚胶股份 ・ 鸿日达 ・ 侨源股份 ・ 康力源 ・ 清研环境 ・ 国缆检测 ・ 东星医疗 ・ 明阳电气 ・ 海科新源 ・ 三博脑科 ・ 美硕科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies